Search results for "Samsung Biologics"

Pediatric Crohn’s: Switching Biologics Yields Similar Remission Rates Despite Lower Blood Drug Levels

Pediatric Crohn’s: Switching Biologics Yields Similar Remission Rates Despite Lower Blood Drug Levels

Pediatric and adolescent Crohn’s disease patients who switch to infliximab after losing responsiveness to adalimumab display lower drug...
Samsung Biologics Slashes Biopharma Development Timeline to 9.5 Months at BioProcess International 2026

Samsung Biologics Slashes Biopharma Development Timeline to 9.5 Months at BioProcess International 2026

Samsung Biologics has unveiled a process innovation case study demonstrating a reduction in biopharmaceutical development timelines from 13 months...
Samsung Biologics to Raise ₩3 Trillion in Rights Offering to Fund ₩2.7 Trillion Acquisition of PolyPeptide Group

Samsung Biologics to Raise ₩3 Trillion in Rights Offering to Fund ₩2.7 Trillion Acquisition of PolyPeptide Group

Samsung Biologics is proceeding with a 3 trillion won ($2.25 billion) rights offering, directing approximately 90% of...
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...
Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms

Samsung Biologics Posts 586.4 Billion Won Q2 Profit, But Labor Uncertainty Looms

Samsung Biologics reported second-quarter revenue in the 1.3 trillion won range this year, a 30% increase from the same...
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal

Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal

Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...
Samsung Biologics Labor Dispute Set for Limited Q2 Impact, but Second-Half Outlook Hinges on Union Deal and U.S. Plant Costs

Samsung Biologics Labor Dispute Set for Limited Q2 Impact, but Second-Half Outlook Hinges on Union Deal and U.S. Plant Costs

With wage and collective bargaining talks between Samsung Biologics and its union still unresolved, analysts expect...
Launch of 'TrumpRX' Sells Drugs at Steep Discounts: Will Celltrion and Samsung Biologics Face Price Pressure?

Launch of 'TrumpRX' Sells Drugs at Steep Discounts: Will Celltrion and Samsung Biologics Face Price Pressure?

The prescription drug sales platform 'TrumpRX', named after U. S. President Donald Trump, has officially launched.
117 Workplace Accidents Recognized at 25 Major Korean Pharma and Biotech Firms Over Five Years

117 Workplace Accidents Recognized at 25 Major Korean Pharma and Biotech Firms Over Five Years

A review of 25 major South Korean pharmaceutical and biotechnology companies revealed 117 recognized industrial...
AI Cancer Gene Analysis and 810 Billion-Won Tech Export Lead South Korea's Top 30 Health Care R&D Achievements

AI Cancer Gene Analysis and 810 Billion-Won Tech Export Lead South Korea's Top 30 Health Care R&D Achievements

The Ministry of Health and Welfare and the Korea Health Industry Development Institute announced on the 8th that they...